News
KLRS
4.320
+0.47%
0.020
Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients
PUBT · 5d ago
KALARIS ANNOUNCES UPCOMING PRESENTATION OF TH103 PHASE 1A CLINICAL DATA AT AMERICAN SOCIETY OF RETINA SPECIALISTS; PH 1B/2 CLINICAL TRIAL ACTIVELY ENROLLING
Reuters · 5d ago
Weekly Report: what happened at KLRS last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at KLRS last week (0608-0612)?
Weekly Report · 06/15 10:34
Kalaris Therapeutics initiated with a Buy at TD Cowen
TipRanks · 06/15 10:10
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
TipRanks · 06/15 09:59
KALARIS THERAPEUTICS INC <KLRS.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/15 09:41
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
Reuters · 06/15 07:49
Kalaris Therapeutics to present Phase 1a TH103 data at Clinical Trials at the Summit 2026
PUBT · 06/12 12:04
Kalaris Therapeutics to present Phase 1a TH103 data in treatment-naive wet AMD patients at CTS 2026
PUBT · 06/12 12:01
Weekly Report: what happened at KLRS last week (0601-0605)?
Weekly Report · 06/08 10:29
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
TipRanks · 06/04 20:55
Kalaris Therapeutics shareholders elect Ferrara, Hallal, Patterson as Class III directors
PUBT · 06/04 20:10
Analysts Offer Insights on Healthcare Companies: Kalaris Therapeutics (KLRS) and Nuvation Bio (NUVB)
TipRanks · 06/01 17:30
Weekly Report: what happened at KLRS last week (0525-0529)?
Weekly Report · 06/01 10:34
CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
TipRanks · 05/25 14:30
Weekly Report: what happened at KLRS last week (0518-0522)?
Weekly Report · 05/25 10:38
Insider Move: Major Kalaris Therapeutics Stock Purchase Signals Growing Confidence
TipRanks · 05/23 02:03
Samsara Opportunity Fund buys 244,300 Kalaris Therapeutics shares for $1.18 million
PUBT · 05/22 23:48
Weekly Report: what happened at KLRS last week (0511-0515)?
Weekly Report · 05/18 10:38
More
Webull provides a variety of real-time KLRS stock news. You can receive the latest news about Kalaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).